why choose us

First received: January 31, 2023

Clinical Trial: PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Renal Cell Carcinoma

Study Type: INTERVENTIONAL


Official Title: Phase 1/2 Study of PRO1160 in Patients With Renal Cell Carcinoma (RCC), Nasopharyngeal Carcinoma (NPC), or Non-Hodgkin Lymphoma (NHL)

Brief Summary: Brief Summary:This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1160 in participants with solid tumors.Participants will have solid tumor or liquid cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).This Phase 1/2 study will have two parts.Part A of the study will find out how much and how frequently PRO1160 should be given to participants.Part B will use the dose and schedule found in Part A to…

Read more